Home » Archive by Category

Articles in Xconomy

West Coast Biotech Roundup: ARCH, Ebola, ViaCyte, Calithera & More

August 28, 2014 – 11:36 am | Edit Post
West Coast Biotech Roundup: ARCH, Ebola, ViaCyte, Calithera & More

Lots of news this week up and down the coast and up and down the biotech food chain. We’ve got a new twist (or fold, if you prefer) on academic Ebola research at the University of Washington,…

[[Click headline to continue reading.]]

AirStrip Raises $25M to Expand into Home Health, Foreign Markets

August 27, 2014 – 7:34 am | Edit Post
AirStrip Raises $25M to Expand into Home Health, Foreign Markets

AirStrip, a San Antonio, TX-based company integrating mobile health and IT technologies, has raised $25 million in a strategic funding round that includes new and existing investors. In a statement,…

[[Click headline to continue reading.]]

San Diego Venture Group Names Mike Krenn as New President

August 27, 2014 – 5:00 am | Edit Post
San Diego Venture Group Names Mike Krenn as New President

The San Diego Venture Group is announcing a change in command. Mike Krenn, a veteran San Diego marketing and business development executive, is succeeding Dave Titus as president of the nonprofit…

[[Click headline to continue reading.]]

Coelacanths And Other IPO Thoughts Before The Autumn Markets Return

August 26, 2014 – 6:48 am | Edit Post
Coelacanths And Other IPO Thoughts Before The Autumn Markets Return

Ah, the final week of summer. Would that it could go on forever. And thanks for reading this on your mobile device with your toes in the sand. Just don’t forget to take a dip or toss a Frisbee…

[[Click headline to continue reading.]]

Roche To Pay $8.3B For Intermune: Who’s Next In Pulmonary Fibrosis?

August 25, 2014 – 7:03 am | Edit Post
Roche To Pay $8.3B For Intermune: Who’s Next In Pulmonary Fibrosis?

Swiss pharmaceutical giant Roche said Sunday it would buy Intermune (NASDAQ: ITMN) of Brisbane, CA, for $8.3 billion. It’s by far the high water mark of a growing wave in recent years of deals…

[[Click headline to continue reading.]]

BioKier Takes a Shot at a New Kind of Diabetes Drug

August 25, 2014 – 4:00 am | Edit Post
BioKier Takes a Shot at a New Kind of Diabetes Drug

Diabetics know all too well that needle sticks are a routine part of managing their disease. Insulin injections have been part of the diabetes standard of care for decades. And in recent years, a new…

[[Click headline to continue reading.]]

Biotech Unveils Drug for Viral Infections Tied to Cervical Cancer

August 22, 2014 – 4:00 am | Edit Post
Biotech Unveils Drug for Viral Infections Tied to Cervical Cancer

A small San Diego biotech has identified a drug that appears to prevent several subtypes of the human papillomavirus (HPV) from replicating—including the two HPV subtypes that cause 70 percent…

[[Click headline to continue reading.]]

West Coast Biotech Roundup: Ebola, Mapp, Tekmira, ViaCyte & More

August 21, 2014 – 11:09 am | Edit Post
West Coast Biotech Roundup: Ebola, Mapp, Tekmira, ViaCyte & More

Big news this morning: two Americans treated with an experimental Ebola treatment have recovered and are now out of the hospital. (A third person, a Spaniard, who received the treatment unfortunately…

[[Click headline to continue reading.]]

Sanford-Burnham Seeks Improved Pharma Ties with New CEO from GSK

August 19, 2014 – 5:02 pm | Edit Post
Sanford-Burnham Seeks Improved Pharma Ties with New CEO from GSK

Following an executive search that took about 18 months, San Diego’s Sanford-Burnham Medical Research Institute named a new CEO today. He is Perry Nisen, a pediatric cancer specialist who specialized…

[[Click headline to continue reading.]]

HealthQuest Capital Raises $110M for Debut Fund with Medtech Focus

August 19, 2014 – 3:00 am | Edit Post
HealthQuest Capital Raises $110M for Debut Fund with Medtech Focus

HealthQuest Capital, founded last year by Sofinnova Ventures partner Garheng Kong, says it has raised $110 million for its debut fund and already has invested in several medical technology and…

[[Click headline to continue reading.]]